This content is in French.
Curcumin in prostate cancer: a promising therapy supported by nanotechnology
4 novembre 2025
By Carolina Lima | Published on November 4, 2025 | 3 min readProstate cancer (PCa) remains one of the most prevalent cancers in men worldwide, often progressing to treatment-resistant stages. In recent years, curcumin—a polyphenolic compound derived from Curcuma longa has gained attention for its multi-targeted anticancer properties. A recent systematic review published in BMC Cancer (2025) highli
By Carolina Lima | Published on November 4, 2025 | 3 min read
Prostate cancer (PCa) remains one of the most prevalent cancers in men worldwide, often progressing to treatment-resistant stages. In recent years, curcumin—a polyphenolic compound derived from Curcuma longa has gained attention for its multi-targeted anticancer properties. A recent systematic review published in BMC Cancer (2025) highlights preclinical evidence on how curcumin acts at the molecular level in PCa and how nanotechnology improves its therapeutic potential.
Prostate cancer (PCa) remains one of the most prevalent cancers in men worldwide, often progressing to treatment-resistant stages. In recent years, curcumin—a polyphenolic compound derived from Curcuma longa has gained attention for its multi-targeted anticancer properties. A recent systematic review published in BMC Cancer (2025) highlights preclinical evidence on how curcumin acts at the molecular level in PCa and how nanotechnology improves its therapeutic potential.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Esmaeli, M., & Dehghanpour Dehabadi, M. (2025). Curcumin in prostate cancer: A systematic review of molecular mechanisms and nanoformulated therapeutic strategies. BMC Cancer, 25, 1609.
View the source
